TimesSquare Capital Management LLC Purchases Shares of 111,545 Krystal Biotech, Inc. $KRYS

TimesSquare Capital Management LLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, Holdings Channel reports. The firm purchased 111,545 shares of the company’s stock, valued at approximately $41,458,000.

A number of other hedge funds have also modified their holdings of KRYS. UMB Bank n.a. increased its stake in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares in the last quarter. Optimize Financial Inc lifted its stake in Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after buying an additional 40 shares in the last quarter. Regal Investment Advisors LLC grew its holdings in Krystal Biotech by 1.0% during the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock valued at $1,075,000 after buying an additional 44 shares during the last quarter. Torray Investment Partners LLC increased its position in Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after buying an additional 47 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in Krystal Biotech by 0.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock worth $1,537,000 after buying an additional 53 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,642 shares of company stock worth $16,471,923 in the last 90 days. 13.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Chardan Capital upgraded Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research note on Friday. They issued an “outperform” rating and a $400.00 target price for the company. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Finally, TD Cowen raised their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Krystal Biotech currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Krystal Biotech Stock Performance

Shares of KRYS opened at $335.73 on Tuesday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The company has a market capitalization of $9.94 billion, a PE ratio of 42.07 and a beta of 0.53. The stock has a fifty day moving average of $345.06 and a two-hundred day moving average of $299.80.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.